Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
		Dec. 31, 2020	Dec. 31, 2020
Selling, general and administrative	[1]	$ 49,243	$ 103,387
Interest expense	[2]	2,609	6,908
Sumitomo Dainippon Pharma Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan
Interest expense		2,569	6,868
Majority Shareholder
Selling, general and administrative		$ 1,671	$ 3,076

[1] Includes $1,337 and $3,784 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2021, respectively. Includes $1,671 and $3,076 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2020, respectively (see Note 5).

[2] Includes $2,871 and $8,660 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and nine months ended December 31, 2021, respectively. Includes $2,569 and $6,868 of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the three and nine months ended December 31, 2020, respectively (see Note 5).